Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice

Richard W Joseph, Gurkamal Chatta, Ulka Vaishampayan

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

Original languageEnglish (US)
Pages (from-to)142-148
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume35
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Renal Cell Carcinoma
Sirolimus
Immunotherapy
Vascular Endothelial Growth Factor A
Antibody Formation
Therapeutics
Safety
nivolumab

Keywords

  • Advanced renal cell carcinoma
  • Immune checkpoint inhibitor
  • Immunotherapy agents
  • Nivolumab
  • PD-1 inhibitor
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Nivolumab treatment for advanced renal cell carcinoma : Considerations for clinical practice. / Joseph, Richard W; Chatta, Gurkamal; Vaishampayan, Ulka.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 35, No. 4, 01.04.2017, p. 142-148.

Research output: Contribution to journalReview article

@article{efe225a26a4340729667f5f762883342,
title = "Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice",
abstract = "Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.",
keywords = "Advanced renal cell carcinoma, Immune checkpoint inhibitor, Immunotherapy agents, Nivolumab, PD-1 inhibitor, Second-line therapy",
author = "Joseph, {Richard W} and Gurkamal Chatta and Ulka Vaishampayan",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.urolonc.2017.01.017",
language = "English (US)",
volume = "35",
pages = "142--148",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Nivolumab treatment for advanced renal cell carcinoma

T2 - Considerations for clinical practice

AU - Joseph, Richard W

AU - Chatta, Gurkamal

AU - Vaishampayan, Ulka

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

AB - Background Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. Methods and Purpose This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.

KW - Advanced renal cell carcinoma

KW - Immune checkpoint inhibitor

KW - Immunotherapy agents

KW - Nivolumab

KW - PD-1 inhibitor

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=85014124224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014124224&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2017.01.017

DO - 10.1016/j.urolonc.2017.01.017

M3 - Review article

C2 - 28259541

AN - SCOPUS:85014124224

VL - 35

SP - 142

EP - 148

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -